Jagsonpal Pharmaceuticals Reports Decline in Key Financial Metrics for March 2025
Jagsonpal Pharmaceuticals has announced its financial results for the quarter ending March 2025, showing a decline in key performance indicators. Profit Before Tax is reported at Rs 6.15 crore, while Profit After Tax stands at Rs 6.74 crore. Net sales reached Rs 58.56 crore, reflecting a downward trend.
Jagsonpal Pharmaceuticals has recently reported its financial results for the quarter ending March 2025, revealing notable trends within its performance metrics. The company, operating in the Pharmaceuticals & Drugs industry, has experienced a revision in its evaluation, with its score adjusting to 7 from 21 over the past three months.The financial data indicates a decline in key performance indicators. Profit Before Tax (PBT) for the quarter stands at Rs 6.15 crore, reflecting a significant shift compared to the average PBT of Rs 9.48 crore from the previous four quarters, marking a notable change in the near-term trend. Similarly, Profit After Tax (PAT) has also shown a decrease, reported at Rs 6.74 crore, down from an average of Rs 8.91 crore in the preceding quarters. Additionally, net sales have been reported at Rs 58.56 crore, which is lower than the average of Rs 63.41 crore from the last four quarters, indicating a downward trend in sales performance.
Furthermore, the company recorded its highest non-operating income in five quarters at Rs 2.77 crore, although this increase may not be indicative of sustainable growth from non-business activities.
For more insights, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
